Last reviewed · How we verify
Placebo to MK-954H
Placebo to MK-954H does not have an active pharmacological mechanism; it is used as a control in clinical trials.
At a glance
| Generic name | Placebo to MK-954H |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo is an inactive substance designed to mimic the appearance of the active drug. It serves as a control to help researchers determine the true effect of the active drug in clinical trials.
Approved indications
Common side effects
Key clinical trials
- A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) (PHASE3)
- MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to MK-954H CI brief — competitive landscape report
- Placebo to MK-954H updates RSS · CI watch RSS
- Organon and Co portfolio CI